Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.

ABSTRACT:

Background

Patients receiving maintenance dialysis represent a high-risk, immune-compromised population with 15%-25% COVID-19 mortality rate who were unrepresented in clinical trials of mRNA vaccines.

Methods

All patients receiving maintenance dialysis who received two doses of SARS-CoV-2 mRNA vaccines with antibody test results drawn ≥14 days after the second dose, as documented in the electronic health record through March 18, 2021, were included. Response was on the basis of levels of Ig-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike-antigen (seropositive ≥2 U/L) using an FDA-approved semiquantitative chemiluminescent assay (ADVIA Centaur XP/XPT COV2G).

Results

Among 186 patients on dialysis from 30 clinics in eight states tested 23±8 d

SUBMITTER: Lacson E 

PROVIDER: S-EPMC8806103 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature